skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.08d (Release date: 2017-08-28)
SearchBox Top
SearchBox Bottom
Oregovomab (Code C1784)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Oregovomab

Definition: A murine monoclonal antibody that attaches to the tumor-associated antigen CA125. Vaccination with monoclonal antibody B43.13 may stimulate a host cytotoxic immune response against tumor cells that express CA125. (NCI04)

NCI-GLOSS Definition: A monoclonal antibody that is being studied in the treatment of ovarian cancer. Monoclonal antibodies are made in the laboratory and can locate and bind to substances in the body, including cancer cells. Oregovomab binds to the CA-125 antigen, which is found on most ovarian cancer cells.

Display Name: Oregovomab

Label: Oregovomab

NCI Thesaurus Code: C1784 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C0664207  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
MoAb B43.13
Monoclonal Antibody B43.13
OvaRex Monoclonal Antibody B43.13

External Source Codes: 
CAS Registry Number 213327-37-8 (see NLM ChemIDplus info)
PDQ Closed Trial Search ID 43251
PDQ Open Trial Search ID 43251 (check for NCI PDQ open clinical trial info)
UMLS CUI C0664207

Other Properties:
     Name Value (qualifiers indented underneath)
Accepted_Therapeutic_Use_For Epithelial ovarian cancer
code C1784
Contributing_Source CTRP
Contributing_Source FDA
Legacy_Concept_Name Monoclonal_Antibody_B43_13
Semantic_Type Amino Acid, Peptide, or Protein
Semantic_Type Immunologic Factor

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom